Vir Biotechnology, Inc. (VIR)

Vir Biotechnology Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	211.1	222.95	241.58	848.63	347.82	436.58
Short-Term Investments	394.92	682.4	1,281	1,553	360.33	300.29
Cash & Short-Term Investments	606.02	905.35	1,522	2,402	708.15	736.86
Cash Growth	-47.35%	-40.53%	-36.62%	239.20%	-3.90%	92.17%
Accounts Receivable	-	-	-	-	773.08	-
Other Receivables	5.2	5.1	11.6	28.9	-	1.9
Receivables	5.2	5.1	11.6	28.9	773.08	1.9
Prepaid Expenses	36.27	42.63	40.95	57.84	73	25.61
Restricted Cash	88.22	89.39	13.27	12.68	8.59	7.99
Other Current Assets	-	-	-	17.62	-	-
Total Current Assets	735.71	1,042	1,588	2,519	1,563	772.37
Property, Plant & Equipment	125.65	122.86	167.2	188.17	130.05	79.89
Long-Term Investments	286.1	190.02	105.28	23.93	201.39	-
Goodwill	16.94	16.94	16.94	16.94	16.94	16.94
Other Intangible Assets	8	8.12	22.57	32.76	33.29	33.82
Other Long-Term Assets	20.14	18.42	18.86	21.23	9.78	15.75
Total Assets	1,193	1,399	1,919	2,802	1,954	918.76
Accounts Payable	12.23	5.08	6.33	6.42	6.52	5.08
Accrued Expenses	62.72	66.53	82.15	462.07	129.54	69.84
Current Portion of Leases	8.83	7.75	12.87	4.14	3.93	3.63
Current Income Taxes Payable	-	-	-	15.23	6.22	-
Current Unearned Revenue	10.11	12.65	64.85	15.52	98.21	6.45
Other Current Liabilities	11.12	27.65	9.2	7.65	96.83	14.07
Total Current Liabilities	105	119.66	175.41	511.03	341.24	99.06
Long-Term Leases	93.41	90.14	111.67	123.84	133.56	66.56
Long-Term Unearned Revenue	-	-	-	53.21	3.82	3.82
Long-Term Deferred Tax Liabilities	-	-	-	-	18.44	3.25
Other Long-Term Liabilities	46.65	38.63	41.74	36.05	25.36	29.22
Total Liabilities	245.06	248.43	328.82	724.13	522.42	201.91
Common Stock	0.01	0.01	0.01	0.01	0.01	0.01
Additional Paid-In Capital	1,941	1,912	1,829	1,710	1,572	1,385
Retained Earnings	-991.71	-759.78	-237.82	377.24	-138.6	-667.18
Comprehensive Income & Other	-2.22	-1.72	-0.82	-9.12	-1.1	-1.28
Total Common Equity	947.47	1,150	1,590	2,078	1,432	716.85
Shareholders' Equity	947.47	1,150	1,590	2,078	1,432	716.85
Total Liabilities & Equity	1,193	1,399	1,919	2,802	1,954	918.76
Total Debt	102.23	97.89	124.54	127.97	137.49	70.18
Net Cash (Debt)	503.79	807.46	1,398	2,274	570.66	666.68
Net Cash Growth	-51.40%	-42.24%	-38.53%	298.50%	-14.40%	73.98%
Net Cash Per Share	3.67	5.93	10.42	16.87	4.28	5.59
Filing Date Shares Outstanding	138.92	137.14	135.03	133.53	132.3	127.84
Total Common Shares Outstanding	138.89	136.96	134.78	133.24	131.16	127.42
Working Capital	630.7	922.8	1,413	2,008	1,222	673.3
Book Value Per Share	6.82	8.40	11.80	15.60	10.92	5.63
Tangible Book Value	922.54	1,125	1,551	2,028	1,382	666.1
Tangible Book Value Per Share	6.64	8.22	11.51	15.22	10.53	5.23
Machinery	45.12	44.9	49.4	41.93	22.57	18.77
Construction In Progress	3.41	1.07	0.23	-	26.93	1.14
Leasehold Improvements	53.83	53.99	80.29	84.42	7.83	7.27

Updated May 8, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q